Genesis Drug Discovery & Development

What Genesis Drug Discovery & Development does

Genesis Drug Discovery & Development (GD3), founded in 2017 and headquartered in Hamilton, New Jersey, operates as a fully integrated Contract Research Organization (CRO) providing fee-for-service drug discovery and development support across the full preclinical-to-clinical continuum. The company is a wholly-owned subsidiary of diversified conglomerate Genesis Global Group. GD3 organizes its service delivery into four operating divisions — Chemistry (medicinal chemistry, organic synthesis, process chemistry, and analytical chemistry/in vitro ADME), Biochemistry & Bioanalytical (in vitro biology, DMPK, and ocular efficacy models), Disease Modeling (in vivo pharmacology, PK/PD, huMice humanized mouse models, SARRP radiation platform, and in vivo imaging), and Preclinical-Toxicology (delivered through acquired Comparative Biosciences, Inc.). A clinical services arm is operated through JSS Medical Research, acquired in 2023, extending capabilities into Phase I-III trial management with regional offices in Canada, Colombia, India, and Poland.

GD3's technology stack centers on AAALAC-accredited vivarium infrastructure spanning over 49,000 sq ft across Hamilton NJ, Portage MI, and Sunnyvale CA facilities, plus GLP- and non-GLP-compliant study capabilities for regulatory-grade preclinical work. Core proprietary assets include a library of over 150 well-characterized patient-derived xenograft (PDX) oncology models, a portfolio of specialized ocular disease models, huMice humanized mouse platforms, and specialized instrumentation such as the Xstrahl SARRP image-guided micro-irradiator, SCIEX/Thermo LC-MS/MS bioanalytical platforms, Meso Scale Discovery electrochemiluminescence immunoassays, and in vivo bioluminescence/fluorescence imaging. The company also offers AAV cloning and packaging services for gene and cell therapy applications. GD3 maintains HIPAA compliance and AAALAC International accreditation, supporting FDA-grade preclinical submissions.

The business model is project-based fee-for-service: GD3 earns revenue through direct enterprise sales to pharmaceutical, biotechnology, nutraceutical, medical device companies, academic institutions, and government agencies, with pricing custom-quoted per project. Go-to-market relies on direct sales engagement, an active LinkedIn presence, and participation in industry events such as the ARE and BVS Summer Evening Event in Cambridge, MA. Customer engagement spans target discovery through IND filing and Phase I-III clinical trial management for small molecules, biologics, cell therapies, and gene therapies, with primary customer segments being pharmaceutical and biotechnology companies followed by academic/nonprofit and nutraceutical/medical device adjacencies.

Name

Genesis Drug Discovery & Development

Legal name

Genesis Drug Discovery & Development

Website

https://gd3services.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Genesis Drug Discovery & Development (GD3) is a fully integrated US-based Contract Research Organization providing fee-for-service preclinical drug discovery and clinical trial support to pharmaceutical, biotechnology, nutraceutical, medical device, academic, and government clients across facilities in the US, Canada, Colombia, India, and Poland.

Ownership category

akta.pro rank

Product category

Contract Research Organization (Drug Discovery & Preclinical Development)

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

In Vivo Pharmacology (Efficacy/PD Models) (HLAGAFAA), GLP Toxicology (Repeat-Dose, Acute/Subacute) (HLAGAFAD), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Contract research organization
• Drug discovery services
• Preclinical research services
• Medicinal chemistry
• Bioanalytical services

Headquarters

HQ city

Robbinsville

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. CRO Services - Contract Research: GD3 operates as a Contract Research Organization providing fee-for-service research services to pharmaceutical, biotech, nutraceutical, medical device companies, academic institutions, government agencies, and nonprofits. Revenue is generated through project-based contracts for drug discovery and development services spanning chemistry, bioanalytical, disease modeling, and preclinical toxicology services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

GD3 is a fully integrated Contract Research Organization (CRO) providing fee-for-service drug discovery and preclinical development services. Offerings span medicinal chemistry, organic synthesis, process chemistry, analytical chemistry, in vitro and in vivo DMPK/bioanalytical services, disease modeling using rodent models (including over 150 PDX oncology models, humanized mice, and ocular disease models), and GLP/non-GLP preclinical toxicology across multiple species. Through its 2023 acquisition of JSS Medical Research, GD3 also supports Phase I–III clinical trial management.

Product overview

Genesis Drug Discovery & Development (GD3) is a fully integrated CRO providing drug discovery services from target discovery through IND filing and managing Phase I-III clinical trials. The company operates through four main divisions: Chemistry Division (medicinal chemistry, organic synthesis, process chemistry, analytical chemistry/ADME), Biochemistry & Bioanalytical Division (in vitro biology, DMPK, ocular efficacy models), Disease Modeling Division (in vivo models, PK/PD services, tolerability/toxicology, platforms including huMice and SARRP), and Preclinical-Toxicology Division (via Comparative Biosciences). GD3 also acquired JSS Medical Research in 2023 to expand clinical services. The company specializes in serving pharmaceutical, biotech, nutraceutical, and medical device companies with capabilities spanning small molecules, biologics, cell therapies, and gene therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• Chemistry Division Fully integrated chemistry CRO services spanning synthetic organic chemistry and medicinal chemistry, including drug discovery, process chemistry, and custom synthesis from early lead identification through clinical development. Offered to pharmaceutical and biotech clients.

Named customers4 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Two partnerships are on record, tiered core and minor.

• JSS Medical ResearchcoreStrategic or Co-development Partner · 10 May 2023GD3 acquired JSS Medical Research, a clinical research organization based in Montreal, Canada with regional offices in Colombia, India, and Poland. The acquisition expands GD3's clinical services portfolio and enables fully integrated drug development support for pharmaceutical, biotech, nutraceutical, and medical device companies. The merger enhances global reach and service offerings.
• Comparative Biosciences, Inc.minorStrategic or Co-development PartnerComparative Biosciences, Inc. is referenced as a partner under GD3's Preclinical-Toxicology division, providing GLP toxicology services in multiple species including mouse, rat, rabbit, dog and minipig.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Charles River Laboratories: Largest pure-play preclinical CRO globally with deep discovery, safety assessment, and manufacturing services across small molecules and biologics; directly comparable to GD3's integrated discovery-to-IND offering but at vastly greater scale and global footprint.
• Labcorp Drug Development (formerly Covance): Diversified CRO offering preclinical through clinical services to pharma and biotech; competes with GD3 for outsourced drug discovery work and represents the kind of large preferred-provider sponsor that mid-sized CROs like GD3 must compete against for enterprise wins.
• Wuxi AppTec: Global CRO/CDMO with extensive preclinical discovery, DMPK, toxicology, and clinical capabilities; competes with GD3 across virtually all service lines and operates at a scale that enables aggressive pricing on standard studies.
• IQVIA: World's largest clinical CRO with growing preclinical and lab services capabilities; competes with GD3's clinical arm (JSS Medical Research) for Phase I-III work and increasingly bundles in preclinical services.
• ICON plc: Global CRO offering clinical, bioanalytical, and post-approval services; competes with GD3 for outsourced drug development programs, particularly on the clinical side following the JSS acquisition.

Direct peers

• Pharmaron: Integrated CRO/CDMO with end-to-end drug discovery, medicinal chemistry, DMPK, in vivo pharmacology, and safety assessment services from China/UK/US sites; one of the closest service-model comps to GD3 and a direct competitor for biotech preclinical outsourcing.
• Eurofins Discovery: Division of Eurofins Scientific offering medicinal chemistry, in vitro ADME, in vivo pharmacology, and safety assessment services; overlaps with GD3's chemistry and disease-modeling divisions and competes for mid-sized biotech preclinical budgets.
• Inotiv: Preclinical CRO specializing in rodent models, toxicology, and research models for pharma/biotech; directly comparable to GD3's disease-modeling and preclinical-toxicology divisions.
• Frontage Laboratories: US-headquartered CRO providing bioanalytical, DMPK, CMC, and preclinical services with US/China footprint; closely comparable to GD3's bioanalytical and chemistry divisions and a frequent competitor for biotech preclinical outsourcing.

Emerging players

• BioDuro (part of Asymchem): Integrated discovery, DMPK, and development CRO with strong US-China operations; comparable mid-sized peer competing for biotech preclinical programs in medicinal chemistry and bioanalysis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gd3services

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genesis Drug Discovery & Development